At the Retina Foundation, our Laboratory Directors often partner with various pharmaceutical and biotechnology companies to conduct clinical trials and …
In this video, you will walk through a typical patient experience at the Retina Foundation with Abigail Christie, Research Associate. This experience is relevant for patients diagnosed with AMD and referred to the Retina Foundation for research and treatment opportunities.
LEARN MORE ABOUT OUR AMD PATIENT CENTER
Treating Age-Related Macular Degeneration (AMD)
There is no cure, or treatment, for dry age-related macular degeneration (AMD) at this time. Individuals diagnosed with advanced wet AMD can receive injections of therapeutic drugs in the eye to slow the progression of vision loss. Patients that are able to receive therapeutic injections will seek treatment with their eye doctor.
Approximately ninety-five percent of AMD patients are diagnosed with dry AMD. Researchers at the Retina Foundation are working diligently to find treatments for these individuals. Funding for this research is a crucial part of discovering treatments. Our AMD research is supported by individuals, foundations, and pharmaceutical/biotechnology corporations.
Should you have any questions about clinical trials being conducted at the Retina Foundation, or should you wish to join a trial, please contact our AMD clinical research staff at amd@retinafoundation.org or 214.363.3911, ext. 400.
AMD CLINICAL STUDIES WE ARE CURRENTLY ENROLLING FOR:
Alexion
For detailed information go to clinicaltrials.gov NCT#: 05019521
Study Title: A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Genentech GR42558
For detailed information go to clinicaltrials.gov NCT#: 03972709
Study Title: A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GALLEGO)
Genentech GR42163
For detailed information go to clinicaltrials.gov NCT#: 04615325
Study Title: A Phase Ia Multicenter, Open -Label, Single Dose, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogencity of Intravitreal Injections of RO7303359 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Gyroscope Horizon
For detailed information go to clinicaltrials.gov NCT#: 04566445
Study Title: A Phase II, Open-label, Outcomes-assessor Masked, Multicentre, Randomised, Controlled Study to Evaluate the Safety and Efficacy of Two Doses of GT005 Administered as a Single Subretinal Injection in Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration
Ophthotech OPH2005
For detailed information go to clinicaltrials.gov NCT#: 03364153
Study Title: A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease
Ionis Golden
For detailed information go to clinicaltrials.gov NCT#: 03815825
Study Title: A Phase 2, Randomized Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
Read about our research initiatives for age-related macular degeneration.
Researchers at the Retina Foundation are working diligently to find treatments for patients diagnosed with dry age-related macular degeneration (AMD). Learn more about the clinical trials we are currently enrolling for.
Our researchers are working to develop a drug delivery device for patients with AMD. It is a small Polymer device that slowly releases therapeutic drugs as needed over a period of weeks, months or years as prescribed by your physician.
Age-related macular degeneration can be detected in a routine eye exam. One of the most common early signs of macular degeneration is the presence of drusen — tiny yellow deposits under the retina — or pigment clumping. Research is looking at the role drusen degeneration plays in AMD.
August 26, 2021
At the Retina Foundation, our Laboratory Directors often partner with various pharmaceutical and biotechnology companies to conduct clinical trials and …
May 15, 2020
Yi-Zhong Wang, Ph.D., Director, Macular Function Laboratory, discusses visual function and imaging evaluation for patients with retinal diseases and his …
Sign up to receive emails from Retina Foundation that will keep you up-to-date on our research and events.
Contact Us
Please check all that apply:
How did you learn about the
Retina Foundation?
Request an Appointment
Please complete this form if you are interested in speaking to a member of our team about your AMD.
all fields required